Skip to main content
Xenon Pharmaceuticals Inc. logo

Xenon Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · XENE ISIN · CA98420N1050 LEI · 549300XV44Q9Z1MIPQ03 US Manufacturing
Open in API
Filings indexed 746 across all filing types
Latest filing 2017-03-14 Director's Dealing
Country CA Canada
Listing US XENE

About Xenon Pharmaceuticals Inc.

https://www.xenon-pharma.com/

Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company dedicated to the discovery, clinical development, and commercialization of therapeutics for neurological and psychiatric disorders. The company leverages its expertise in human genetics and a deep understanding of ion channel biology to develop medicines that modulate ion channels, targeting the central and peripheral nervous systems. Its late-stage pipeline includes azetukalner, an investigational candidate being developed for the treatment of epilepsy and depression.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2017-03-14 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated March 13, 2017, by Xenon Pharmaceuticals Inc. The content focuses on the approval of 2016 non-equity incentive plan payments, 2017 base salaries, and stock option grants for certain executive officers. It includes detailed compensation information and references to the company's proxy statement for additional executive compensation details. The key item reported is Item 5.02, which relates to the departure, election, or appointment of directors or officers and their compensatory arrangements. This matches the description of Board/Management Information filings, which announce changes or updates related to the company's board or senior management. The document is not a full annual report, earnings release, or proxy statement but a current report on management compensation decisions. Therefore, the appropriate classification is MANG (Board/Management Information). The document length (6741 characters) supports it being a substantive report rather than a brief announcement or certification.
2017-03-14 English
FORM 8-K FILING SEDAR NOTICE OF AGM
AGM Information Classification · 95% confidence The document is a Form 8-K filing dated March 9, 2017, by Xenon Pharmaceuticals Inc. It announces the meeting, record date, and other information related to the 2017 annual meeting of shareholders. The text references a SEDAR filing attached as Exhibit 99.1, which contains the detailed information. The document is relatively short (2555 characters) and primarily serves as an announcement of the AGM information rather than the full AGM materials or minutes themselves. Therefore, it fits best as an AGM Information announcement. Given the nature of the filing and the content, the classification is AGM-R with high confidence.
2017-03-09 English
S-8 - EQUITY PLAN
Capital/Financing Update Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by Xenon Pharmaceuticals Inc. It registers additional securities under the company's 2014 Equity Incentive Plan. The document includes details about the securities to be registered, incorporation by reference of prior filings including the 10-K annual report, and exhibits related to the equity plan. Form S-8 is specifically used for registering securities to be offered under employee benefit plans and is a capital/financing related filing. It is not an annual report, earnings release, or other financial report. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is the actual registration statement, not just an announcement or certification.
2017-03-08 English
XENE-10K-20161231
Annual Report FY 2016
2017-03-08 English
8-K - Q4 EARNINGS RELEASE
Earnings Release Classification · 95% confidence The document is a Form 8-K filing dated March 8, 2017, from Xenon Pharmaceuticals Inc. It announces the company's financial results for the year ended December 31, 2016, via a press release attached as Exhibit 99.1. The text explicitly states that the information is furnished but not filed with the SEC, and the document itself is short (2810 characters). It does not contain the full financial statements or detailed financial analysis but rather announces the earnings release. According to the rules, an initial announcement of quarterly or periodical financial results (key highlights only) corresponds to an Earnings Release (ER). Therefore, this document is best classified as an Earnings Release (ER).
2017-03-08 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.